TBX1 and neoplasm: CDK inhibitors (particularly inhibitors of CDK7 and CDK9) have been shown to disrupt the autoregulatory landscape of brachyury, downregulate cellular brachyury levels in a limited number of chordoma cell lines, and reduce tumour growth in vivo [14,15].